University of Liverpool

UK AI Firm Quantexa, Mersey Care NHS Foundation Trust, and the University of Liverpool’s Civic Health Innovation Labs Partner to Create a Groundbreaking Global AI Hub for Health and Social Care in Liverpool

Retrieved on: 
Monday, March 18, 2024
Civic, OLS, Health, Innovation, Associate, Mental, Partnership, University of Liverpool, Caregiver, Patient, Mental health, NHS, University, AI, Private sector, Social work, Ecosystem, Health and social care, Engineering, Nursing

Based within CHIL is the Mental Health Research for Innovation Centre (M-RIC), a partnership between Mersey Care NHS Foundation Trust and the University of Liverpool, aimed to tackle global challenges in mental health, including increasing levels of illness.

Key Points: 
  • Based within CHIL is the Mental Health Research for Innovation Centre (M-RIC), a partnership between Mersey Care NHS Foundation Trust and the University of Liverpool, aimed to tackle global challenges in mental health, including increasing levels of illness.
  • It will support building a trusted data foundation to develop better drug and digital therapies, as well as to better coordinate care services.
  • Quantexa will be working alongside teams from the University of Liverpool, NHS Cheshire and Merseyside Integrated Care Board, and Mersey Care NHS Foundation Trust.
  • Vishal Marria, CEO of Quantexa, said: “Quantexa’s vision is to work with university and NHS partners to address global current challenges in UK care programs.

Insulet to Present Results from First Omnipod® 5 Randomized Controlled Trial (OP5-003) at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)

Retrieved on: 
Tuesday, March 5, 2024
Health Technology, Diabetes, Manufacturing, Technology, Pharmaceutical, Other Consumer, General Health, Medical Devices, Clinical Trials, Wearables, Mobile Technology, Other Manufacturing, Science, Consumer, Health, Research, Real-World Evidence, Cloud, OBE, Adolescence, Doctor of Philosophy, Treatment, Medical director, Database, University, Hypoglycemia, Associate, AID, University of Liverpool, Standard of care, Data, Therapy, Insulin, Convention, Randomized controlled trial, CGM, Pathway, Use, Conference, MDI, Automation, Endocrinology, MD, DASH, ATTD, Medicare, University of Edinburgh, Edge Hill University, Corporation, Chairperson, Medical device

“We are thrilled to unveil the results of our inaugural randomized controlled trial with groundbreaking insights from international Omnipod 5 users,” said Dr. Trang Ly MBBS, FRACP, PhD, Insulet Senior Vice President and Medical Director.

Key Points: 
  • “We are thrilled to unveil the results of our inaugural randomized controlled trial with groundbreaking insights from international Omnipod 5 users,” said Dr. Trang Ly MBBS, FRACP, PhD, Insulet Senior Vice President and Medical Director.
  • It is the first Omnipod 5 randomized controlled trial to date, and the first time the system has been evaluated in participants living outside of the United States.
  • This presentation will take place on Thursday, March 7 at 12:00 p.m. CET and Friday, March 8 at 10:30 a.m. CET.
  • Insulet representatives will be available to provide Omnipod product demonstrations to conference attendees, offering healthcare professionals the chance to experience Omnipod DASH and Omnipod 5 first-hand.

Mark Ross to Retire as President of Chevron Shipping Company, Succeeded by Barbara Pickering

Retrieved on: 
Wednesday, January 24, 2024
Maritime, Transport, Logistics, Supply Chain Management, Oil, Gas, Energy, Other Transport, Seamanship, OCIMF, Dragon Oil, University of Liverpool, Multimedia, Chemical engineering, Champaign–Urbana metropolitan area, Business administration, Terminal, University, Ship, Downstream, Petroleum

After 33 years of distinguished service, Mark Ross, President of Chevron Shipping Company, has elected to retire effective May 1, 2024.

Key Points: 
  • After 33 years of distinguished service, Mark Ross, President of Chevron Shipping Company, has elected to retire effective May 1, 2024.
  • Barbara Pickering, currently Vice President of Operations, Chevron Shipping Company, will succeed Mark as President.
  • View the full release here: https://www.businesswire.com/news/home/20240124396325/en/
    Mark has led Chevron Shipping Company since 2015.
  • “Under Mark’s leadership, Chevron Shipping Company has delivered exceptional safety and environmental performance and has greatly expanded its marine capabilities,” said Colin Parfitt, President Midstream.

Medical Education Market size to grow by USD 208.73 billion from 2022 to 2027, Market is fragmented due to the presence of prominent companies like All India Institute of Medical Sciences, KP Bernard J. Tyson School of Medicine and Mayo Clinic, and many m

Retrieved on: 
Friday, January 5, 2024
University of Eastern Finland, Yale University, Geography, University of Liverpool, TTUHSC, Learning, University of Oxford, National university, National University of Singapore, University of Washington, University of California, University of New England, Johns Hopkins University, Education, Stanford University, Western Governors University, USD, University, Knowledge, Mayo Clinic, Growth, University of Cambridge, Grand Canyon University, Harvard Medical School, University of Alabama, Nursing

The medical education market is fragmented owing to the presence of many global and regional companies.

Key Points: 
  • The medical education market is fragmented owing to the presence of many global and regional companies.
  • Download a Sample before buying
    KP Bernard J. Tyson School of Medicine - The company offers medical education such as a Bachelor of Science (BS) in Health Sciences.
  • National University of Singapore - The company offers medical education such as M.D.M.B.A., M.D.Ph.D., M.D.M.P.H., and M.D.MSHCM, and others.
  • The higher education testing and assessment market is estimated to grow at a CAGR of 6.32% between 2022 and 2027.

Replimune Presents Updated Data on RP2 in Uveal Melanoma during Plenary Session at the 20th International Congress of the Society for Melanoma Research

Retrieved on: 
Wednesday, November 8, 2023
Survival, FRCP, Research, Uveal melanoma, International Congress on Tuberculosis, Trae tha Truth, Nivolumab, University of Liverpool, Bachelor of Medicine, Bachelor of Surgery, DOR, Melanoma, Liver, Clatterbridge Cancer Centre NHS Foundation Trust, Doctor of Philosophy, Ipilimumab, Development, Lung, 8th Plenary Session of the Central Committee of the League of Communists of Serbia, Disease, Hypotension, Liver disease, Metastasis, RP2, Itch, Uvea, Immunotherapy, ORR, Chills, University, Society, Melanoma Research, Patient, Toxicity, Fatigue, Pharmaceutical industry, Fever

The data were presented by Dr. Joseph Sacco during a Plenary Session at the 20th International Congress of the Society for Melanoma Research in Philadelphia.

Key Points: 
  • The data were presented by Dr. Joseph Sacco during a Plenary Session at the 20th International Congress of the Society for Melanoma Research in Philadelphia.
  • The median duration of response (DOR) at the data cutoff was 11.47 months (range of 2.78 to 21.22 with responses ongoing).
  • RP2 was generally well tolerated both as monotherapy and in combination with nivolumab with no additive adverse events observed.
  • “These data from the trial cohort evaluating RP2 as monotherapy and in combination with nivolumab in metastatic uveal melanoma are highly promising,” said Robert Coffin, President and Chief Research & Development Officer at Replimune.

Blue Water Biotech Appoints Dr. Neil J. Campbell as President and CEO and Bruce Harmon as CFO

Retrieved on: 
Tuesday, October 10, 2023
United Nations, MBA, Life Technologies, Howard Hughes Medical Institute, Celera Corporation, Webster University, Missouri State University, Norwich University, Nanotechnology, Duquesne University, Laboratory, Artificial intelligence, Abbott Laboratories, Johns Hopkins, Science, Biophysical environment, CFO, University of Liverpool, United, Management, Tech

CINCINNATI, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (Nasdaq: BWV), which is focused on developing and commercializing transformational therapies to address significant global health challenges, today announced the appointments of Dr. Neil J. Campbell as President and CEO and Bruce Harmon as CFO, effective immediately.

Key Points: 
  • CINCINNATI, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (Nasdaq: BWV), which is focused on developing and commercializing transformational therapies to address significant global health challenges, today announced the appointments of Dr. Neil J. Campbell as President and CEO and Bruce Harmon as CFO, effective immediately.
  • James Sapirstein, Blue Water Biotech’s Lead Independent Director, said, "Neil is an exceptional businessman and leader who is well-suited for Blue Water Biotech.
  • Immediately prior to joining Blue Water Biotech, he was an independent consultant who served in the outsourced CFO capacity for multiple publicly traded companies since 2008.
  • During this time, Mr. Harmon was CFO of Marizyme Inc., the CFO of bioAffinity Technologies Inc. and a director of Dale Biotech LLC.

Meeting Protocol Worldwide Expands Leadership Team with Four New Appointments

Retrieved on: 
Monday, October 9, 2023
University, Senior, Data science, Hospital, MBA, Acquisition, Kellogg School, Master of Science in Management, PRA Health Sciences, Berkeley, SVKM's NMIMS, Culture, University of North Carolina at Charlotte, Bayer, Chapel Hill, Industrial, Doctor of Philosophy, Environment, Growth, Marketing, The arts, Software, Executive, Actigraphy, University of Liverpool, Scout (operating system), Management, Pfizer, Science

"At Meeting Protocol Worldwide, we are proud of the incredible talent we have added to our leadership team, who will take us into our next phase of growth with clients across the globe.

Key Points: 
  • "At Meeting Protocol Worldwide, we are proud of the incredible talent we have added to our leadership team, who will take us into our next phase of growth with clients across the globe.
  • Each of these individuals brings with them decades of experience in sales, marketing, operations, and finance," said Paige Bingham, CEO, Meeting Protocol Worldwide.
  • Kuno van der Post, Ph.D., serves as Chief Revenue Officer, where he spearheads marketing and sales efforts across the Meeting Protocol Worldwide family of brands.
  • Mr. Fontenault's additional experience includes leadership positions at ER Squared, INC.; Kendle International, Pfizer, EResearchTechnology, Purdue Pharma L.P., and Bayer Healthcare.

Transgene Advances Its Innovative Immunotherapy Pipeline and Extends Financial Visibility Until the End of 2024

Retrieved on: 
Wednesday, September 20, 2023
Biotechnology, Other Health, Health, Pharmaceutical, Oncology, MSD, Head, MBA, Phase II, Doctor of Philosophy, Journal, Patient, Potyvirus, Epitope, Merck, NEC, La Jolla Institute for Immunology, FRCP, University, HPV16, Research, Lung cancer, Merck & Co., De novo, University of Liverpool, CD8, Cervical cancer, CTL, Biology, Immunology, Phase, Safety, AACR, E6, Immune system, University of Lausanne, European Journal, KOL, European Journal of Cancer Prevention, Bank statement, AstraZeneca, E7, ASCO, Euronext Paris, Statutory auditor, Combined, Immunotherapy, Tumor microenvironment, Pharmaceutical industry, Vaccine, Computer data storage, Cancer, MD, TG4050, Transgene

We are planning together with our partner NEC to start a randomized Phase II trial in 2024.

Key Points: 
  • We are planning together with our partner NEC to start a randomized Phase II trial in 2024.
  • Transgene and NEC intend to start a randomized Phase II trial in the adjuvant setting of head and neck cancer in 2024.
  • Transgene is assessing all options to ensure data read out in 2024 from the trial as previously communicated.
  • The Board of Directors of Transgene met on September 20, 2023, and approved the financial statements for the six-month period ended June 30, 2023.

Clinical Study Finds Aetrex Orthotics Reduce Pain and Fear of Falling for Seniors

Retrieved on: 
Thursday, September 14, 2023
Research, Seniors, Other Retail, Clinical Trials, Health, Consumer, General Health, Retail, Science, Foam, DSM-IV codes, NRS, Human, Liverpool School of Tropical Medicine, Hip, University of Liverpool, Perception, Foot, Ageing, University of Liverpool School of Medicine, Proprioception, Woman, Employment, Multimedia, Trial of the century, Pain, Physical, Muscle weakness, Synthetic control method, Aintree University Hospital, Risk, University, Randomized controlled trial, Metatarsal bones, Shoe, Fear of falling, Mental health, Falling, Knee, Poultry farming, Geriatrics

A recent study found that Aetrex Premium Memory Foam Orthotics , both with and without metatarsal support, are clinically proven to reduce common sources of pain (i.e., back, foot, hip, knee and ankle pain) and the fear of falling for seniors.

Key Points: 
  • A recent study found that Aetrex Premium Memory Foam Orthotics , both with and without metatarsal support, are clinically proven to reduce common sources of pain (i.e., back, foot, hip, knee and ankle pain) and the fear of falling for seniors.
  • View the full release here: https://www.businesswire.com/news/home/20230914845282/en/
    Left: Aetrex Premium Memory Foam Orthotic Right: Aetrex Premium Memory Foam Orthotic with Metatarsal Pad (Graphic: Business Wire)
    Both foot pain and fear of falling are obstacles to healthy aging.
  • Seniors who report a fear of falling more than double their risk of actually falling.
  • The study also shows orthotics reduce the fear of falling in seniors.

The Galien Foundation Presents 2023 Prix Galien UK Awards at the Natural History Museum, London

Retrieved on: 
Friday, May 12, 2023
University, College, Saint George, Consultant, University of Edinburgh College of Medicine and Veterinary Medicine, Innovation, Research, University of Liverpool, Digital health, World Health Organization, Chandos Chair of Medicine and Anatomy, University of Edinburgh, Imperial College London, NHS trust, Senior advisor, Therapy, Veterinary medicine, Respiratory Medicine, Pharmaceutical industry, Management, Medicine

LONDON, May 12, 2023 /PRNewswire/ -- The Galien Foundation, the premier global institution dedicated to honouring innovators in life sciences, announced winners for the 2023 Prix Galien UK Awards last night at the Natural History Museum, London. Awards for "Best Biotechnology Product," "Best Pharmaceutical Product," "Best Medical Technology" and "Best Digital Health Solution" were awarded to industry leaders dedicated to innovation that improves the human condition. A winner was also announced in the newest award category, "Best Public Sector Innovation," to recognise innovations that are funded and driven by the UK government via the NHS and not-for-profit organisations.

Key Points: 
  • "The Prix Galien Awards Committee, who reviewed this year's candidates and selected the award winners, were inspired by the work of the teams behind these innovations, which were developed to prevent, treat, and cure diseases," said Professor Sir Mark Walport, Honorary Distinguished Professor of Medicine, Imperial College, and Prix Galien UK Committee Chair.
  • "Congratulations to our winners and all award candidates, and thank you for your continued dedication to research and its applications for health improvement."
  • Honorary Distinguished Professor of Medicine, Imperial College, London UK
    Chair, NICE Technology Appraisal Committee and Consultant, St. George's NHS Trust Professor
    Health Technology Director, Senior Consultant, Hardian Health & Senior Adviser and Consultant, World Health Organization's Department of Digital Health and Innovation
    David Weatherall Chair of Medicine, University of Liverpool, Liverpool
    Christison Chair of Therapeutics & Clinical Pharmacology, University of Edinburgh
    Vice Principal and Head of the College of Medicine and Veterinary Medicine, Sir John Crofton Professor of Respiratory Medicine, University of Edinburgh